Rice Hall James & Associates LLC Invests $2.91 Million in iRadimed Corporation $IRMD
Rice Hall James & Associates LLC has acquired a new stake in iRadimed Corporation (NASDAQ:IRMD), purchasing 30,444 shares valued at approximately $2.91 million. This investment comes as iRadimed reports strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating from Wall Street analysts, despite some recent downgrades. The company also declared a quarterly dividend of $0.20 per share.
iRadimed (NASDAQ:IRMD) Shares Cross Below 200 Day Moving Average - Time to Sell?
iRadimed (NASDAQ:IRMD) shares recently fell below their 200-day moving average, trading at $88.02 against an average of $94.77. Despite this, the company maintains a "Moderate Buy" consensus rating with a $120 target price and exceeded recent earnings and revenue estimates. iRadimed also declared a quarterly dividend of $0.20, representing an annualized yield of 0.9%.
IRMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of IRADIMED CORPORATION (IRMD), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's main revenue source is MRI Compatible Patient Vital Signs Monitoring Systems, and it boasts strong gross, operating, and net margins, alongside a solid Return on Equity. A competitive analysis against DRTS and BVS highlights IRMD's strong market position and efficiency.
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed reported its Q2 2026 financial results, highlighting successful initial production of its new 3870 MR IV pump system and strong customer acceptance, with bookings more than double units shipped. Despite temporary gross margin compression due to manufacturing ramp-up inefficiencies, the company reaffirmed its full-year 2026 guidance, expecting improved efficiencies and continued growth in the latter half of the year, driven by the replacement of older pump systems and strong monitor sales.
iRadimed (NASDAQ:IRMD) Cut to "Hold" at Wall Street Zen
iRadimed (NASDAQ:IRMD) has been downgraded to a "Hold" rating by Wall Street Zen and Weiss Ratings, despite analysts maintaining a "Moderate Buy" consensus with an average price target of $120. The company recently surpassed quarterly earnings and revenue expectations. CEO Roger E. Susi sold 5,000 shares, and other insiders have sold shares totaling approximately $1.52 million in the last quarter, though institutional investors own a significant portion of the company.
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed reported its Q2 2026 financial results, achieving manufacturing targets for its new 3870 MR IV pump system and seeing strong customer acceptance for the four-channel quad pump. Despite a temporary decline in gross margins due to production ramp-up inefficiencies, the company reaffirmed its full-year 2026 guidance, expecting improved efficiencies and record gross margins by Q4. The company highlighted significant replacement opportunities for older pump systems and strong demand for its patient monitors, while also declaring a quarterly cash dividend.
IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin
IRADIMED (IRMD) stock dropped 4.6% despite posting Q2 revenue of US$20.5m and non-GAAP EPS of US$0.46. The company experienced a deliberate hit to its gross margin, which compressed from 78% to 74%, as the new 3870 MR intravenous pump moved into a higher volume production phase. While bookings outpaced shipments and full-year guidance was reaffirmed, bears remain concerned about margin risk due to the company's concentrated product set and the 3870 ramp.
IRADIMED CORP Q2 2026: Revenue $20.47M, EPS $0.41— 10-Q Summary
IRADIMED CORP reported its second-quarter 2026 results, showing flat revenue year-over-year at $20.47M, while net income and diluted EPS decreased due to margin pressure from new-product production. Revenue growth was driven by device launches and disposables, with a notable shift in geographic mix as international sales significantly increased. The company's gross margin was impacted by initial production inefficiencies, but cash from operations improved after a facility expansion.
IRadimed: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for IRadimed. The content is concise and directly presents the company's performance for the quarter.
IRADIMED: More Than 70% of New Pump Orders Were Four-Pump Setups
IRADIMED (NASDAQ: IRMD) announced its Q2 2026 financial results, reporting $20.5 million in revenue, up 0.5% year-over-year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. The company reaffirmed its full-year 2026 guidance, expecting $91.0–$96.0 million in revenue and GAAP EPS of $1.90–$2.05, and declared a quarterly cash dividend of $0.20 per share. A key highlight was the strong adoption of its new 3870 MR IV pump, with over 70% of new orders being for the four-pump "quad stack" configuration, indicating a significant product and customer mix transition.
Iradimed reports Q2 revenue $20.5M, EPS $0.41; raises dividend to $0.20 and reaffirms 2026 guidance
Iradimed (IRMD) reported Q2 revenue of $20.5 million and diluted EPS of $0.41, alongside declaring a $0.20 quarterly dividend. The company reaffirmed its Q3 and full-year 2026 revenue and GAAP EPS guidance, anticipating revenue between $91.0M–$96.0M and GAAP EPS of $1.90–$2.05 for the full year. Iradimed also launched production of its next-generation 3870 MR IV pump, expecting revenue and efficiency gains in the second half of 2026.
IRadimed: Q2 Earnings Snapshot
IRadimed Corp. (IRMD) reported a second-quarter profit of $5.2 million, or 41 cents per share, with adjusted earnings of 46 cents per share. The company generated $20.5 million in revenue for the period. Looking ahead, IRadimed forecasts third-quarter earnings between 54 and 59 cents per share on revenue of $23 million to $24.5 million, and full-year earnings of $2.09 to $2.24 per share with revenue between $91 million and $96 million.
Renaissance Technologies LLC Sells 15,700 Shares of iRadimed Corporation $IRMD
Renaissance Technologies LLC reduced its stake in iRadimed Corporation by 3.4% during the first quarter, selling 15,700 shares but still retaining 440,712 shares valued at approximately $42.4 million. Despite this sale, institutional investors collectively own 92.34% of the company, and analysts maintain a "Buy" rating with an average price target of $120. iRadimed also exceeded first-quarter earnings and revenue expectations and announced a quarterly dividend.
Iradimed earnings on deck as growth momentum faces Q2 test
Iradimed (IRMD) is set to report its second-quarter earnings, with analysts expecting $0.44 earnings per share on $20.35 million in revenue, a sequential decline from Q1. Investors will focus on the performance of its new MRI-compatible IV infusion pump, margin sustainability, and management's reaffirmation of full-year guidance. Despite anticipated Q2 softness, Wall Street maintains a "Strong Buy" rating with a target price suggesting 25% upside.
Record Results, New MRI Pump And Dividend Hike Might Change The Case For Investing In IRADIMED (IRMD)
IRADIMED (IRMD) recently reported record 2025 results, strong Q1 2026, and FDA clearance for its upgraded MRidium 3870 MRI IV infusion pump, alongside an increased quarterly dividend. These developments, particularly the new pump expected to drive replacement demand, are highlighted as potentially reshaping the investment narrative for the company. The article suggests that while the new pump presents a significant catalyst, investors should also consider the concentration risk around a single product family.
IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of IRadimed Corp (IRMD), noting its current financial score is 9.60, ranking it 2nd in the Healthcare Equipment & Supplies industry. It highlights the company's robust financial status and high operating efficiency, with a recent quarterly revenue of $21.98M (12.65% year-over-year increase) and a 24.12% year-over-year net profit increase. The analysis further breaks down scores for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, indicating areas where specific data has not yet been disclosed by the company.
BlackRock (IRMD holder) discloses 5.01% IRADIMED CORP stake on Schedule 13G
BlackRock, Inc. has disclosed a passive ownership stake of 5.01% in IRADIMED CORP (IRMD) common stock, as reported on a Schedule 13G filing. As of June 30, 2026, BlackRock beneficially owned 641,128 shares, with sole voting power over 622,925 shares and sole dispositive power over all 641,128 shares. The filing specifies that while various underlying clients have rights to dividends or sale proceeds, no single client holds more than five percent of IRADIMED's outstanding common shares.
IRMD|IRadimed Corp|Price:94.860|Chg%:+0.370
This article provides a comprehensive stock analysis of IRadimed Corp (IRMD) by TradingKey, highlighting its strong fundamentals, high growth potential, and institutional confidence. The company specializes in MRI-compatible medical devices, with revenue growth averaging 27.84% annually over the last three years and high dividend payouts. Despite a high P/E ratio indicating it might be overvalued, analysts have a "Buy" rating with a target price suggesting a 24.88% upside.
IRadimed Corp (IRMD) Stock Price Live, Chart & News - TradingKey
IRadimed Corp (IRMD) is currently trading at $92.495, up 1.41%. The company specializes in MRI-compatible medical devices, including IV infusion pumps and vital signs monitors. Analysts rate IRMD as a "Buy" with a target price of $118.00, indicating a 29.37% upside.
IRadimed Corp (IRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for IRadimed Corp (IRMD), segmenting its revenue by business and by region. The data, updated on April 6, analyzes contributions from MRI-compatible IV infusion pumps, patient vital signs monitoring systems, disposables, extended warranty amortization, and ferro magnetic detection systems. It also shows a significant portion of its revenue originating from the United States compared to international markets.
IRadimed Corp (IRMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of dividend payouts for IRadimed Corp (IRMD), detailing interim and final cash dividends with their respective record, payment, and ex-dividend dates. Over the past five years, IRadimed Corp has distributed a total of 39.46 million USD in dividends. The company's basic stock information, including market capitalization and P/E ratio, is also presented.
IRadimed Corp (IRMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of IRadimed Corp (IRMD), outlining major individual and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over time, and notable shareholder activity including changes in positions. The report also lists several ETFs that hold IRMD shares.
IRadimed Corp (IRMD) Cash Flow
This article provides a detailed historical cash flow statement for IRadimed Corp (IRMD), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures for various cash flow components from FY2013Q1 through FY2026Q1, along with year-over-year percentage changes. The report also includes an FAQ section defining different types of cash flow and summarizing IRadimed Corp's recent performance in these areas.
IRMD|IRadimed Corp|Price:94.490|Chg%:+0.630
This article presents a detailed financial overview of IRadimed Corp (IRMD), including its latest stock price, market capitalization, and P/E ratio. It provides access to the company's income statement, balance sheet, and cash flow statement, along with quarterly and annual financial indicators. The report also highlights key financial figures from the FY2025 earnings report and upcoming earnings dates and forecasts.
Before market open, IRADIMED will release Q2 results July 31
IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its Q2 2026 financial results before the market opens on Friday, July 31, 2026. Management will host a conference call at 11:00 a.m. Eastern Time the same day to discuss the results and answer questions. The company leads in developing MRI-compatible medical devices, including a non-magnetic IV infusion pump system and a patient vital signs monitoring system.
IRADIMED (IRMD) As MRI Pump Upgrade Narrative Points To Fair Value Above The Stock
IRADIMED (IRMD) stock has gained renewed attention, with analysts suggesting an 18% undervaluation and a fair value of $118 per share, largely due to the new 3870 MRI-compatible IV pump. While the upgrade narrative points to future revenue growth and a replacement cycle, the stock's current P/E ratio of 52.5x is elevated compared to industry averages. Investors are advised to consider both the growth potential from the new product and the potentially high valuation multiples.
Iradimed Corp (IRMD) Q3 2024 Earnings Report - Results, Call & Slides
Iradimed Corp (IRMD) reported its Q3 2024 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of $0.43 against a consensus of $0.41, and actual revenue of $18.33 million against an expected $18.15 million, reflecting an 11.04% year-over-year growth. The earnings call took place on October 31, 2024, and the next earnings report is estimated for July 30, 2026.
Price to book forward of IRadimed Corp. – LS:A118V4
This article provides financial information for IRadimed Corp. (LS:A118V4), specifically focusing on its price-to-book forward ratio. It includes an overview of the company's financials on TradingView, such as market data provided by ICE Data Services and reference data from FactSet.
IRMD - Iradimed Corp Latest SEC Filings
This article provides the latest SEC filings and a comprehensive overview of Iradimed Corp (IRMD) financials and performance metrics. It details key financial figures such as market cap, income, sales, and various ratios, alongside stock performance, insider and institutional ownership, and analyst recommendations.
Price to book forward of IRadimed Corp. – HAN:46K
This article provides the "Price to book forward" metric for IRadimed Corp. (HAN:46K) trading on the Hannover Stock Exchange. It is a financial data point without further analysis or contextual information.
Enterprise value to revenue forward of IRadimed Corp. – HAN:46K
This article presents the enterprise value to revenue forward for IRadimed Corp. (HAN:46K) as listed on the Hannover Stock Exchange. Although the article provides no specific numerical data, it frames the company's financial metric within the context of a stock exchange listing. The content primarily focuses on navigation, market data sources, and general information about TradingView rather than detailed financial analysis of IRadimed Corp.
IRadimed Corp. Actuals & Estimates (DUS:46K)
This article provides an overview of IRadimed Corp. (DUS:46K) financial actuals and estimates, including income statement, balance sheet, and cash flow data. It covers analyst forecasts for the stock, historical price performance, upcoming earnings dates, and details on past earnings, revenue, net income, dividends, and EBITDA.
46K Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for IRadimed Corp. (46K) stock, based on analyst opinions. It includes details on maximum and minimum price estimates, past financial performance, upcoming earnings dates, dividend information, and company metrics like EBITDA and employee count. The piece also addresses frequently asked questions about trading 46K shares.
IRadimed Corp. Actuals & Estimates (NASDAQ:IRMD)
This article provides an overview of iRadimed Corporation (NASDAQ: IRMD) including financial actuals, estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, earnings, revenue, dividends, and volatility, along with an analyst consensus and technical analysis. The company is set to release its next earnings report on July 30, 2026.
Iradimed (NASDAQ: IRMD) investors approve directors, auditor and pay
Iradimed Corporation's shareholders held their annual meeting, where they elected Roger Susi, Monty Allen, Joe Kiani, Hilda Scharen-Guivel, and James Hawkins to the board of directors. They also approved RSM US LLP as the independent auditor for the fiscal year ending December 31, 2026, and passed an advisory resolution concerning executive compensation. All proposals received sufficient support from stockholders.
Form 4 Iradimed Co For: 23 June By Investing.com
This article from Investing.com is a regulatory filing update titled "Form 4 Iradimed Co For: 23 June." It reports on the Form 4 filing for Iradimed Co (IRMD) made on June 23rd, 2026, indicating insider transactions for the company. The article contains the title, publication date, and the stock symbol, but no further details about the transactions.
Form 4 Iradimed Co For: 23 June By Investing.com
This article from Investing.com reports that a Form 4 for Iradimed Co was filed on June 23rd. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be submitted by company insiders, such as directors, officers, and major shareholders, whenever they buy or sell shares of their own company's stock. The article mentions the stock symbol IRMD, indicating a focus on this particular company's insider transactions.
IRADIMED (IRMD) CFO converts RSUs to stock and uses 2,319 shares for taxes
IRADIMED CFO John Glenn converted 5,796 restricted stock units (RSUs) into common shares on June 20, 2026. He then disposed of 2,319 shares to cover tax obligations, which was a tax-withholding transaction, not an open-market sale. Following these transactions, Glenn directly holds 11,937 shares of IRADIMED common stock.
Form 4 Iradimed Co For: 23 June By Investing.com
This article reports on a Form 4 filing for Iradimed Co (IRMD) related to transactions on June 23. While the article's core content is brief, it serves primarily as a placeholder to display current market data and popular news headlines, including updates on EV battery durability, NATO news, and OPEC+ oil output decisions. It also showcases various market indices, commodity prices, and trending stocks.
IRADIMED (IRMD) Stock Could Be 21.9% Undervalued on Its MRI Pump Upgrade Narrative
IRADIMED (IRMD) is currently valued by one narrative as 21.9% undervalued at $92.20 per share, with a fair value target of $118, primarily due to the anticipated replacement cycle driven by its new 3870 MRI compatible IV pump. While this narrative projects significant revenue growth and improved margins, the company's high P/E ratio of 49.9x compared to peers (37.4x) and a fair ratio of 19x suggests potential valuation risk if sentiment shifts or growth expectations are not met. Investors are encouraged to analyze the risks and rewards, considering both the product upgrade potential and valuation concerns.
IRMD Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for IRadimed Corp (IRMD), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. While some indicators like RSI are neutral or sell, the MACD and several moving averages suggest a bullish outlook. Key support is identified at $89.367 and resistance at $98.087.
IRadimed Corp (IRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for IRadimed Corp (IRMD), indicating an earnings forecast score of 8.00 and ranking 66th in its industry. Analysts, based on 2 ratings, have an average price target of $99.00 with a "Buy" recommendation. The company's previous quarter EPS was $0.51 against an expectation of $0.46, with the next quarter's EPS expected at $0.42 and revenue at $20.35M.
IRadimed Corp (IRMD) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for IRadimed Corp (IRMD), highlighting its current risk assessment score of 7.77 and ranking within the Healthcare Equipment & Supplies industry. It details various risk metrics including beta, maximum drawdown, volatility, and Sharpe Ratio, along with liquidity indicators. The report notes the neutral state of the U.S. Dollar Index and its neutral effect on the industry.
IRadimed Corp (IRMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a detailed historical overview of IRadimed Corp's (IRMD) dividend payouts, including future declared dividends. It lists the dividend amount, record date, payment date, and ex-dividend date for various interim and final cash dividends. The report also notes that there is no historical data available for stock splits for IRMD.
IRadimed Corp (IRMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of IRadimed Corp (IRMD), listing major individual and institutional holders. It provides a breakdown of shareholder types and traces institutional shareholding trends over several quarters. The data includes the proportion of shares held and changes in holdings for key shareholders and related ETFs.
IRadimed Corp (IRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for IRadimed Corp (IRMD), categorizing its revenue by business segments and geographical regions. As of April 6, 2024, the company's largest revenue contributors are MRI Compatible IV Infusion Pump Systems and MRI Compatible Patient Vital Signs Monitoring Systems. The United States accounts for the significant majority of its regional revenue.
IRadimed Corp (IRMD) Institutional Confidence
IRadimed Corp (IRMD) has an institutional shareholding score of 5.00, placing it 109th in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion is 65.08%, a 13.11% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 3.45% of outstanding shares.
IRadimed Corp (IRMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IRadimed Corp (IRMD), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, IRMD's price momentum score is 7.36, and the stock is trading between resistance at $98.06 and support at $85.97. Based on the analysis, the overall signal for IRadimed Corp is currently "Sell".
IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial analysis of IRadimed Corp (IRMD), highlighting its strong financial health with a score of 9.60. The company ranks highly in its industry due to robust financial status, high operating efficiency, and significant year-over-year increases in revenue and net profit. The analysis covers various financial dimensions including profitability, quality of earnings, operational efficiency, growth potential, and shareholder returns.
Number of shareholders of IRadimed Corp. – DUS:46K
The article displays an overview of IRadimed Corp. (DUS:46K) on the TradingView platform, focusing on the number of shareholders. It includes sections for financial data, news, community insights, forecasts, and stock information, indicating a market closed status with no recent trades.
